The aim of this report was to assess the added benefit of the fixed-dose combination rilpivirine / emtricitabine / tenofovir compared to the appropriate comparator therapy (ACT) (efavirenz in combination with emtricitabine / tenofovir) in the approved therapeutic indication (human immunodeficiency virus type 1 [HIV-1] infection in antiretroviral-naïve adult patients with a viral load of ≤ 100,000 HIV-1 RNA copies/mL).
http://ift.tt/2t1INtJ
Τετάρτη 14 Ιουνίου 2017
Addendum to Commission A12-02 (Rilpivirine / Emtricitabine / Tenofovir) [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου